Oxidronic Acid

Oxidronic Acid

SCHEMBL393281

O=P(O)(O)C(O)P(=O)(O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
MMP2 P08253 1/20 0.40
THRB P10828 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA2 P00918 1/20 0.36
TYMS P04818 1/20 0.35
LAP3 P28838 2/20 0.35
ANPEP P15144 1/20 0.35
ERAP2 Q6P179 1/20 0.35
PGK1 P00558 3/20 0.33
PGK2 P07205 3/20 0.33
FDPS P14324 2/20 0.33
SLC34A1 Q06495 1/20 0.33
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GABBR2 O75899 1/20 0.32
GABBR1 Q9UBS5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxidronic Acid SCHEMBL29363818 0.96 KDM4E (0.38) KDM4EMMP2THRBMAPK1HSD17B10
Oxidronic Acid SCHEMBL8958458 0.96 KDM4E (0.38) KDM4EMMP2THRBMAPK1HSD17B10
Oxidronic Acid SCHEMBL28460122 0.96 KDM4E (0.38) KDM4EMMP2THRBMAPK1HSD17B10
Oxidronic Acid SCHEMBL1478075 0.96 KDM4E (0.38) KDM4EMMP2THRBMAPK1HSD17B10
Oxidronic Acid SCHEMBL4611796 0.89 KDM4E (0.33) KDM4EMMP2THRBMAPK1HSD17B10
SCHEMBL17954018 0.78 CA2 (0.44) KDM4EMMP2THRBMAPK1HSD17B10
SCHEMBL919194 0.76
Oxidronic Acid SCHEMBL28460123 0.75 SLC34A1 (0.47) KDM4EMMP2THRBMAPK1HSD17B10
Oxidronic Acid SCHEMBL1649745 0.75 SLC34A1 (0.39) KDM4EMMP2THRBMAPK1HSD17B10
SCHEMBL10831667 0.73 KDM4E (0.40) KDM4EMMP2THRBMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619431-A1 METHODS FOR TREATING OR PREVENTING TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Neurimmune AG (CH) 2025-09-24 EP claimed
CN-119089235-B Customer service risk assessment and early warning method and system based on historical data 北京华档致远科技有限公司 2025-05-27 CN claimed
WO-2025054524-A1 METHOD FOR DIAGNOSING AMYLOID DISEASES UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-03-13 WO claimed
CN-119528315-A Stable reducing iron-sulfur-based slurry and preparation method and application thereof 南京师范大学 2025-02-28 CN claimed
CN-119439655-A Corrosion-resistant developing solution and preparation method and application thereof 上海戎洲芯科技有限公司 2025-02-14 CN claimed
CN-119418559-A Hierarchical conflict detection and resolution method based on ADS-B data validity 培风智行(天津)科技有限责任公司 2025-02-11 CN claimed
CN-119220617-A Method for synthesizing pyrrole-2-ethyl formate by lipase catalysis 江南大学 2024-12-31 CN claimed
CN-119089235-A Customer service risk assessment and early warning method and system based on historical data 北京华档致远科技有限公司 2024-12-06 CN claimed
US-20240299568-A1 BONE-SPECIFIC DELIVERY OF POLYPEPTIDES WILLIAM MARSH RICE UNIVERSITY (US) 2024-09-12 US claimed
WO-2024105062-A1 METHODS FOR TREATING OR PREVENTING TRANSTHYRETIN-MEDIATED AMYLOIDOSIS NEURIMMUNE AG (CH) 2024-05-23 WO claimed
EP-0111415-A2 Process for making lyophilized radiographic imaging kit Mallinckrodt, Inc. (a Delaware corporation) (US) 1984-06-20 EP claimed
EP-0111414-A2 Radiographic imaging agents Mallinckrodt, Inc. (a Delaware corporation) (US) 1984-06-20 EP claimed
US-4455291-A IMAGES NEW ENGLAND NUCLEAR CORPORATION (US) 1984-06-19 US claimed
US-4451451-A Radiopharmaceutical composition based on technetium-99m and reagent for making it AMERSHAM INTERNATIONAL PLC (GB) 1984-05-29 US claimed
US-4440646-A HYDROXY OR HALOALKANEPHOSPHONATES PLAINS CHEMICAL DEVELOPMENT CO. (US) 1984-04-03 US claimed
US-4410442-A FATTY ACID THE PROCTER & GAMBLE COMPANY (US) 1983-10-18 US claimed
EP-0078642-A2 Radiopharmaceutical composition based on technetium-99m and reagent for making it AMERSHAM INTERNATIONAL plc (GB) 1983-05-11 EP claimed
US-4240920-A A SURFACTANT, A PEROXY BLEACH AND A PORPHINE BLEACH THE PROCTER & GAMBLE COMPANY (US) 1980-12-23 US claimed
US-4188234-A STABILIZATION OF VINYL POLYMERS, POLYPHOSPHONIC ACID CHELATING AGENT, PROTECTIVE COATINGS PLAINS CHEMICAL DEVELOPMENT CO. (US) 1980-02-12 US claimed
US-4116990-A OF NON-ALKALI METAL IONS WITH PHOSPHORUS CHELATING COMPOUND PLAINS CHEMICAL DEVELOPMENT CO. (US) 1978-09-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299568-A1 BONE-SPECIFIC DELIVERY OF POLYPEPTIDES SOST, BST2, ACP3 KDM4E 4204/4885MMP2 485/4885THRB 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.